Date:6 May, 2022
Your Name:Lingling Bao
Manuscript Title: Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis
patients with renal anemia affected by the COVID-19 pandemic: A retrospective study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present	Medical Health Science	
	manuscript (e.g., funding,	and Technology Project of	
	provision of study materials,	Zhejiang Provincial Health	
	medical writing, article	Commission (2022KY299)	
	processing charges, etc.)	Medical Health Science	
	No time limit for this item.	and Technology Project of	
		Zhejiang Provincial Health	
		Commission (2022KY1105)	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5 Payment or hone lectures, present		None	
speakers bureau			
manuscript writi			
educational ever			
6 Payment for exp	ert	None	
testimony			
7 Support for atter		None	
meetings and/or	travel		
8 Patents planned	issued or	None	
pending	, issued of	NUTE	
pending			
9 Participation on	a Data	None	
Safety Monitorin	ng Board or		
Advisory Board			
10 Leadership or fid		None	
in other board, s	-		
committee or ad	•		
group, paid or ur	•		
11 Stock or stock op	otions	None	
12 Receipt of equip	mont	Nono	
materials, drugs,		None	
writing, gifts or c			
services	Other financial or non-		
	or non-	None	
		None	

This study was supported by the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY299 and 2022KY1105).

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:6 May, 2022
Your Name:Xueyan Bian
Manuscript Title: Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis
patients with renal anemia affected by the COVID-19 pandemic: A retrospective study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the wo	rk
1	All support for the present manuscript (e.g., funding, provision of study materials,	Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY299)	
medical writing, article processing charges, etc.) No time limit for this item.		Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY1105)	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		

	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy	Professional Committee of Renal Disease Prevention and Control, Ningbo Preventive Medical Association	Director
	group, paid or unpaid	Ningbo Nephropathy Society of Traditional Chinese and Western Medicine	Vice director
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY299 and 2022KY1105).

The author is the director of the Professional Committee of Renal Disease Prevention and Control, Ningbo Preventive Medical Association and the vice director of the Ningbo Nephropathy Society of Traditional Chinese and Western medicine.

### Please place an "X" next to the following statement to indicate your agreement:

# \_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:6 May, 2022
Your Name:Aiwei Zhang
Manuscript Title: Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis
patients with renal anemia affected by the COVID-19 pandemic: A retrospective study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present	Medical Health Science	
	manuscript (e.g., funding,	and Technology Project of	
	provision of study materials,	Zhejiang Provincial Health	
	medical writing, article	Commission (2022KY299)	
	processing charges, etc.)	Medical Health Science	
	No time limit for this item.	and Technology Project of	
		Zhejiang Provincial Health	
		Commission (2022KY1105)	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

	[	
5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	None
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment,	None
1	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	None

This study was supported by the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY299 and 2022KY1105).

# Please place an "X" next to the following statement to indicate your agreement:

# \_\_\_ X \_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:6 May, 2022
Your Name:Jiancheng Huang
Manuscript Title: Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis
patients with renal anemia affected by the COVID-19 pandemic: A retrospective study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY299) Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY1105)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

		1	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
0	pending		
	pending		
9	Participation on a Data	None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	NOTE	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
11		NOTE	
12	Receipt of equipment,	None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
13	financial interests		

This study was supported by the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY299 and 2022KY1105).

# Please place an "X" next to the following statement to indicate your agreement:

# \_\_\_ X \_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:6 May, 2022
Your Name:Liling Ren
Manuscript Title: Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis
patients with renal anemia affected by the COVID-19 pandemic: A retrospective study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	pranning of the work
1	All support for the present	Medical Health Science	
	manuscript (e.g., funding,	and Technology Project of	
	provision of study materials,	Zhejiang Provincial Health	
	medical writing, article	Commission (2022KY299)	
	processing charges, etc.)	Medical Health Science	
	No time limit for this item.	and Technology Project of	
		Zhejiang Provincial Health	
		Commission (2022KY1105)	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6		None	
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
0	pending		
9	Participation on a Data	None	
3	-		
	Safety Monitoring Board or Advisory Board		
10		News	
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	None	

This study was supported by the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY299 and 2022KY1105).

# Please place an "X" next to the following statement to indicate your agreement:

# X \_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:6 May, 2022
Your Name:Chunlei Luo
Manuscript Title: Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis
patients with renal anemia affected by the COVID-19 pandemic: A retrospective study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	Medical Health Science	
	manuscript (e.g., funding,	and Technology Project of	
	provision of study materials,	Zhejiang Provincial Health	
	medical writing, article	Commission (2022KY299)	
	processing charges, etc.)	Medical Health Science	
	No time limit for this item.	and Technology Project of	
		Zhejiang Provincial Health	
		Commission (2022KY1105)	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None
	manuscript writing or	
	educational events	
6	Payment for expert testimony	None
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society, committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment,	None
1	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non- financial interests	None

This study was supported by the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2022KY299 and 2022KY1105).

# Please place an "X" next to the following statement to indicate your agreement:

# X \_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.